Mr. Elad Bibi-Aviv reports

SEEGNAL ANNOUNCES LETTER OF INTENT WITH U.S.-BASED CARE FACILITY, MARKING FIRST PENETRATION OF THE AMERICAN HEALTHCARE MARKET

Seegnal Inc. has entered into a letter of intent, dated May 5, 2026, with a United States-based long-term-care provider to conduct a pilot program with Seegnal's clinical decision support platform. The LOI marks Seegnal's first pilot engagement in the United States.

Under the LOI, the parties intend to conduct a pilot program during which Seegnal's platform will analyze prescription data without affecting clinical workflows, with the goal of identifying medication-related risks and optimization opportunities across the resident population. The contemplated pilot is expected to run between eight and 12 weeks from the receipt of data, followed by a potential extended evaluation period. The pilot program is expected to begin shortly following the execution of the LOI.

Approximately 1.2 million Americans live in CMS-certified nursing facilities, a population characterized by advanced age, multiple chronic conditions and high rates of polypharmacy. Adverse drug events are a significant and often preventable source of hospitalization in this population: An estimated 99,628 emergency hospitalizations each year in U.S. adults aged 65 and older are attributable to adverse drug events.

"Long-term-care residents are among the most medication-vulnerable populations in U.S. health care, typically managing multiple chronic conditions, taking many concurrent prescriptions and facing elevated risk of adverse drug events that drive avoidable hospitalizations and pharmacy spend," said Elad Bibi-Aviv, chief executive officer of Seegnal. "Entering the U.S. market through long-term care is a deliberate first step. It is a setting where Seegnal's patient-specific approach to medication safety can demonstrate clinical and economic value quickly, and it provides a repeatable entry point for the broader U.S. commercial expansion we have outlined for the company."

About Seegnal Inc.

Seegnal is an innovative health care technology company dedicated to reducing medication-related harm where care begins. The company's software-as-a-service-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing and advance a more personalized standard of patient care. Seegnal's technology is deployed across health care settings and is used by more than 15,000 clinicians in daily practice.

We seek Safe Harbor.